Evidence map›Paper›PMID 35245934›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022

Impact of Multicomponent Support Strategies on Human Immunodeficiency Virus Virologic Suppression Rates During Coronavirus Disease 2019: An Interrupted Time Series Analysis.

Matthew A Spinelli, Noelle Le Tourneau, David V Glidden, Ling Hsu, Matthew D Hickey, Elizabeth Imbert, Mireya Arreguin, Jennifer P Jain, Jon J Oskarsson, Susan P Buchbinder and 4 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Emerging from the shadows: Trends in HIV ambulatory care, viral load testing, and viral suppression in a U.S. HIV cohort, 2019-2022: Impact of COVID-19 pandemic.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Article
  4. Article
  5. Article
  6. Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023
    Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Matthew A SpinelliDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.ORCID 0000-0001-6368-8664
Noelle Le TourneauDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
David V GliddenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Ling HsuSan Francisco Department of Public Health, San Francisco, California, USA.
Matthew D HickeyDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Elizabeth ImbertDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Mireya ArreguinDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Jennifer P JainDepartment of Psychiatry, University of California, San Francisco, California, USA.
Jon J OskarssonDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Susan P BuchbinderDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Mallory O JohnsonDepartment of Medicine, Division of Prevention Science, University of California, San Francisco, California, USA.
Diane HavlirDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Katerina A ChristopoulosDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.
Monica GandhiDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California, USA.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
Women, Intersectionality, Substance Use and HIV ( WISH)K01DA056306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Payaal Jain · 2022 to 2026
$1.0M
Mentoring Patient-Oriented Research on Advances to Optimize Engagement in HIV CareK24AI167805 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katerina A Christopoulos · 2022 to 2026
$963k
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 VaccinesR21AI167648 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2022 to 2023
$444k
NIAID NIH HHS K24 AI167805NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI158013NIAID NIH HHS R21 AI167648NIAID NIH HHS T32 AI060530NIDA NIH HHS K01 DA056306NIDA NIH HHS L60 DA054664NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

backgroundAfter coronavirus disease 2019 (COVID-19) shelter-in-place (SIP) orders, viral suppression (VS) rates initially decreased within a safety-net human immunodeficiency virus (HIV) clinic in San Francisco, particularly among people living with HIV (PLWH) who are experiencing homelessness. We sought to determine if proactive outreach to provide social services, scaling up of in-person visits, and expansion of housing programs could reverse this decline.

methodsWe assessed VS 24 months before and 13 months after SIP using mixed-effects logistic regression followed by interrupted time series (ITS) analysis to examine changes in the rate of VS per month. Loss to follow-up (LTFU) was assessed via active clinic tracing.

resultsData from 1816 patients were included; the median age was 51 years, 12% were female, and 14% were experiencing unstable housing/homelessness. The adjusted odds of VS increased 1.34 fold following institution of the multicomponent strategies (95% confidence interval [CI], 1.21-1.46). In the ITS analysis, the odds of VS continuously increased 1.05 fold per month over the post-intervention period (95% CI, 1.01-1.08). Among PLWH who previously experienced homelessness and successfully received housing support, the odds of VS were 1.94-fold higher (95% CI, 1.05-3.59). The 1-year LTFU rate was 2.8 per 100 person-years (95% CI, 2.2-3.5).

conclusionsThe VS rate increased following institution of the multicomponent strategies, with a lower LFTU rate compared with prior years. Maintaining in-person care for underserved patients, with flexible telemedicine options, along with provision of social services and permanent expansion of housing programs, will be needed to support VS among underserved populations during the COVID-19 pandemic.

Indexed as

COVID-19HIV InfectionsIll-Housed PersonsFemaleHIVHumansInterrupted Time Series AnalysisMaleMiddle AgedPandemicsCOVID-19HIV virologic suppressionhomelessnesshousing supporttelemedicine

Identifiers

PMID35245934
PMCPMC9129130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.